Merck reported Q1 FY 2016 earnings of $0.89 per share (versus $0.85 in Q1 FY 2015), beating analysts' consensus of $0.85.

The company's quarterly revenues amounted to $9.312 bln (-1.2% y/y), slightly missing consensus estimate of $9.445 bln.

Merck issued guidance for FY 2016, raising EPS to $3.65-3.77 from $3.60-3.75 (versus analysts' consensus estimate of $3.72) and revenues to $39-40.2 bln from $38.7-40.2 bln (versus analysts' consensus estimate of $39.85 bln).

MRK rose to $55.25 (+0.8%) in pre-market trading.